论文部分内容阅读
目的:观察早期使用盐酸氨溴索(沐舒坦)治疗新生儿肺透明膜病的疗效。方法:选择新生儿肺透明膜病患儿100例,按随机数字表分成治疗组50例和对照组50例。2组在相同综合治疗的基础上,治疗组予沐舒坦30mg·kg-1·d-1,分4次,用5%葡萄糖注射液5ml缓慢泵入观察2组患儿治疗后的临床表现,比较2组治疗后新生儿肺透明膜病的发病率、死亡率及药物副反应。结果:治疗组50例HMD发生率3/50,观察组14/50,差异有统计学意义,(x2=治疗组1例死亡,观察组死亡5例,治疗组使用盐酸氨溴索后无1例药物副反应。2组比较,发生率及死亡率差异有显著性(P<0.01)。结论:早期使用沐舒坦对新生儿肺透明膜病有较好疗效,可避免气管插管,减少机械通气率。
Objective: To observe the curative effect of early use of Ambroxol Hydrochloride in the treatment of neonatal hyaline membrane disease. Methods: 100 cases of neonates with hyaline membrane disease were selected and randomly divided into treatment group (50 cases) and control group (50 cases). On the basis of the same comprehensive treatment, the two groups were given mucosolvan 30mg · kg-1 · d-1 in 4 groups, and the clinical manifestations of the two groups were observed after 2-pump infusion of 5% dextrose injection. The incidence, mortality and side effects of hyaline membrane disease were compared between the two groups. Results: In the treatment group, the incidence of HMD in 50 cases was 3/50 and in the observation group was 14/50, the difference was statistically significant (x2 = 1 in the treatment group and 5 in the observation group; 1 in the treatment group after administration of ambroxol hydrochloride Cases of drug side effects .2 group comparison, the incidence and mortality were significantly different (P <0.01) .Conclusion: Early use of ambroxol on neonatal hyaline membrane disease has a good effect, to avoid intubation, reduce the mechanical Ventilation rate.